May 16, 2017 07:44 AM EDT

With a $42M raise and a reverse merger, Synlogic makes a quick flip onto Nasdaq

John Carroll

Editor & Founder

Jose Carlos Gutierrez-Ramos has found the back door to Nasdaq.

The CEO at Cambridge, MA-based Synlogic is executing a reverse merger with the failed Austin-based biotech Mirna Therapeutics, which will put the synthetic biology company into the public market. And in addition, the biotech says that it recently closed a $42 million C round to back its transition into the spotlight of public reporting.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

With a $42M raise and a reverse merger, Synlogic makes a quick flip onto Nasdaq

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

AbbVie makes second deal in a week, betting $8.7B in cash on CNS biotech Cerevel

Pfizer plans to pull out of BIO, following moves by other large drugmakers to reduce lobbying footprint

Aviv Regev leads Genentech's next revolution with AI

FDA approves Novartis drug for rare blood disorder

FDA sends letter to Novartis over Kymriah manufacturing safety concerns

Early prediction of outcomes in DLBCL clinical trials through MRD testing

With a $42M raise and a re­verse merg­er, Syn­log­ic makes a quick flip on­to Nas­daq

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Ab­b­Vie makes sec­ond deal in a week, bet­ting $8.7B in cash on CNS biotech Cerev­el

Pfiz­er plans to pull out of BIO, fol­low­ing moves by oth­er large drug­mak­ers to re­duce lob­by­ing foot­print

Aviv Regev leads Genen­tech's next rev­o­lu­tion with AI

FDA ap­proves No­var­tis drug for rare blood dis­or­der

FDA sends let­ter to No­var­tis over Kym­ri­ah man­u­fac­tur­ing safe­ty con­cerns

Ear­ly pre­dic­tion of out­comes in DL­B­CL clin­i­cal tri­als through MRD test­ing

With a $42M raise and a reverse merger, Synlogic makes a quick flip onto Nasdaq

AbbVie makes second deal in a week, betting $8.7B in cash on CNS biotech Cerevel

Pfizer plans to pull out of BIO, following moves by other large drugmakers to reduce lobbying footprint

Aviv Regev leads Genentech's next revolution with AI

FDA approves Novartis drug for rare blood disorder

FDA sends letter to Novartis over Kymriah manufacturing safety concerns

Early prediction of outcomes in DLBCL clinical trials through MRD testing